12:00 AM
 | 
May 04, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PerCvax: Interim Phase I data

Interim data from an open-label, dose-escalation, U.K. Phase I trial (HCV001) in 36 healthy volunteers showed that 4 weeks after priming, both vector components of the PerCvax vaccine dose-dependently induced HCV-specific T cell responses. Proliferative responses to...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >